AMENDMENTS TO THE CLAIMS

The following **Listing of Claims** will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-53. (**Canceled**)

54. (**Currently Amended**) A method of treating a subject in need of treatment for malaria, wherein the subject is infected with a malaria parasite, the method comprising the step of administering an antimalarial composition comprising a compound that is an inhibitor of fatty acid synthesis in the malaria parasite to the subject, ~~The method of claim 53,~~ wherein the compound ~~inhibitor of fatty acid synthesis~~ is triclosan; ~~, having a formula given below~~:



~~Formula 1~~



triclosan

and wherein the malaria parasite is *P. falciparum* or *P. berghei*.

55. (**Currently Amended**) The method of claim 54 ~~53~~, wherein the composition further comprises one or more known antimalarial agents and a pharmaceutically acceptable adjuvant, diluent, or carrier.

56. (**Previously Presented**) The method of claim 55, wherein the known antimalarial agent is selected from the group consisting of: quinine, atabrine, chloroquine, mefloquine, primaquine, anti-folates, artemisinin, artemether, and artesunate.

57. (**Currently Amended**) The method of claim 54 ~~53~~, wherein the composition is administered by injection.

58. (**Currently Amended**) The method of claim 54 ~~53~~, wherein the amount of triclosan ~~the inhibitor of fatty acid synthesis~~ administered is in the dosage range of 0.03 mg/kg to 100 mg/kg.

59. (**Currently amended**) The method of claim ~~53~~ 54, wherein the triclosan ~~compound~~ inhibits FabI (enoyl ACP reductase) in the malaria parasite.

60. (**Canceled**).

61. (**Canceled**).

62. (**Canceled**).

63. (**Currently amended**) The method of claim ~~53~~ 54, wherein the malaria parasite is *P. falciparum*.